Synapse

← Clinical Cancer Bulletin

Papers in Clinical Cancer Bulletin

Page 1 · newest first

  1. Clinical advances in proton spatially fractionated radiation therapyClinical Cancer Bulletin · 2026
  2. DNA damage omics: concepts, genome-wide mapping technologies, and research perspectivesClinical Cancer Bulletin · 2026
  3. Artificial intelligence for overcoming resistance and safety challenges in cancer stem cell-targeted cellular immunotherapyClinical Cancer Bulletin · 2026
  4. Stereotactic body radiotherapy and the tumor microenvironment in pancreatic ductal adenocarcinoma: from mechanistic remodeling to immunotherapy combinationsClinical Cancer Bulletin · 2026
  5. T cell receptor-engineered T cells for hepatocellular carcinoma: next steps and future perspectivesClinical Cancer Bulletin · 2026
  6. HPV vaccination and cervical cancer deaths: from incidence reduction to mortality preventionClinical Cancer Bulletin · 2026
  7. Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in ChinaClinical Cancer Bulletin · 2026
  8. The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancerClinical Cancer Bulletin · 2026
  9. Exploring mitochondrial central dogma in cancer from a metabolic perspectiveClinical Cancer Bulletin · 2026
  10. Patient-derived tumor organoid co-culture systems as translational platforms for cancer immunotherapy and precision oncologyClinical Cancer Bulletin · 2026
  11. Radiotherapy-induced immunity is real but incomplete: nano-immunoadjuvants as immune amplifiers in radioimmunotherapyClinical Cancer Bulletin · 2026
  12. A heterogeneous multimodal ensemble framework for multi-omics breast cancer prognosisClinical Cancer Bulletin · 2026
  13. The CCL2/CCR2 axis in irradiated tumors: orchestrating immune recruitment and microenvironment remodelingClinical Cancer Bulletin · 2026
  14. Comparative efficacy and safety of postoperative adjuvant therapies after curative resection for hepatocellular carcinoma: a network meta-analysisClinical Cancer Bulletin · 2026
  15. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-associated myocarditis (2026 edition)Clinical Cancer Bulletin · 2026
  16. Targeting HER-2 pathway in presence of cardiac dysfunction: the walk on a tight ropeClinical Cancer Bulletin · 2026
  17. Computational stratification and engineering framework of the PDCD1/CD2 immune axis in triple-negative breast cancerClinical Cancer Bulletin · 2026
  18. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastasis (2025 Edition)Clinical Cancer Bulletin · 2026
  19. Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilitiesClinical Cancer Bulletin · 2026
  20. Global research status and trends in the AI-driven anticancer drug design: a bibliometric analysis of 2011–2025Clinical Cancer Bulletin · 2026
  21. Dual role of interleukin-2 in tumor-infiltrating lymphocyte therapyClinical Cancer Bulletin · 2026
  22. Causal relationships between cerebral cortical architecture and blood cancers: the disease spectrum is different because the brains look differentClinical Cancer Bulletin · 2026
  23. Conditional reprogramming in eyelid tumors: bridging the model gap in meibomian gland carcinomaClinical Cancer Bulletin · 2026
  24. Chinese expert consensus on ultrasound-guided percutaneous lung needle biopsy (2025 Edition)Clinical Cancer Bulletin · 2026
  25. Chinese expert consensus on robotic surgery for colorectal cancer (2025 edition)Clinical Cancer Bulletin · 2026
  26. Chinese expert consensus on the management of adverse events to HER2-targeted antibody–drug conjugates in digestive system cancers (2025 edition)Clinical Cancer Bulletin · 2026
  27. Emerging biomarkers for early detection of lung cancerClinical Cancer Bulletin · 2025
  28. Emerging biomarkers for early detection of lung cancerClinical Cancer Bulletin · 2025
  29. Advancing cancer care through artificial intelligence: from innovative models to clinical decision-making and regulatory integrationClinical Cancer Bulletin · 2025
  30. Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospectsClinical Cancer Bulletin · 2025
  31. Multi-omics and Mendelian randomization reveal ABC transporter alternative splicing as a pan-cancer prognostic marker and therapeutic targetClinical Cancer Bulletin · 2025
  32. Friend or foe? Multi-omics analysis unravels the complex identity of key pyroptosis factor CASP9 in clear cell renal cell carcinomaClinical Cancer Bulletin · 2025
  33. Application and Advances of Adoptive Cell Therapy for MelanomaClinical Cancer Bulletin · 2025
  34. Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors (2025)Clinical Cancer Bulletin · 2025
  35. Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive reviewClinical Cancer Bulletin · 2025
  36. Prognostic and therapeutic implications of lipid metabolism-related lncRNAs in lung adenocarcinoma: a comprehensive analysis integrating transcriptomics, Mendelian randomization, and immunotherapy sensitivityClinical Cancer Bulletin · 2025
  37. Small molecules in lung cancer targeted therapy: a two-decade bibliometric analysis and visualization (2005–2024)Clinical Cancer Bulletin · 2025
  38. Immunotherapy for hepatocellular carcinomaClinical Cancer Bulletin · 2025
  39. Immune checkpoint inhibitor-associated myocardial infarction in a patient with lung cancer undergoing six cycles of immunotherapy: a case reportClinical Cancer Bulletin · 2025
  40. Therapeutic vaccine strategies in cancer: advances, challenges, and future directionsClinical Cancer Bulletin · 2025
  41. Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensusClinical Cancer Bulletin · 2025
  42. Management of multisystemic irAEs associated with atezolizumab/tiragolumab combination therapy in a patient with lung adenocarcinoma: case report and reviewClinical Cancer Bulletin · 2025
  43. Pembrolizumab-induced pemphigoid nodularis manifesting as an erythema multiforme-like eruption: a case reportClinical Cancer Bulletin · 2025
  44. Comprehensive evaluation of clinical prognostic parameters in a real-world cohort of 812 patients with multiple myelomaClinical Cancer Bulletin · 2025
  45. Rethinking contralateral breast cancer: latest insights on risk, prevention, and outcomesClinical Cancer Bulletin · 2025
  46. Identification of a lysosome-related prognostic signature to predict prognosis, tumor microenvironment and therapeutic responses in lung adenocarcinomaClinical Cancer Bulletin · 2025
  47. Proteomics efforts for hepatocellular carcinoma drug developmentClinical Cancer Bulletin · 2024
  48. Insights for the immunotherapy in malignant melanoma: a new revolutionClinical Cancer Bulletin · 2024
  49. Primary cutaneous scrotal angiosarcoma: a case report and literature reviewClinical Cancer Bulletin · 2024
  50. MyD88's function in the emergence and growth of tumorsClinical Cancer Bulletin · 2024